APR Nov/Dec 2022 - 56

»
FACILITY TOUR
»
FACILITY TOUR
Eurofins BioPharma Product Testing
ATMP and Cell and Gene Therapy Testing Services for the Global Market
The global biopharmaceutical industry is continually innovating and
looking forward to discover the next class of therapies to treat and
cure patients around the world.
Cell and gene therapies, which fall into the broader category of
drugs known as Advanced Therapy Medicinal Products (ATMPs) have
emerged as an incredibly promising class of treatments that have
shown the ability to treat and even cure many individuals with diseases
for which there was previously little to no hope.
Cell and gene therapies work by substituting the missing or defective
gene and resulting protein or cell causing the disease's symptoms. Cell
therapy treats diseases by restoring or altering targeted sets of cells or
56 |
| November/December 2022
by using cells to carry a therapy throughout the body. Gene therapy
operates differently by replacing, inactivating or introducing genes
into cells - either inside the body (in vivo) or outside of the body (ex
vivo). Some therapies are considered both cell and gene therapies.
These therapies work by modifying genes in specific types of cells and
inserting them into the body.
Current market forecasts predict the cell and gene therapy market
to grow by almost $10B by 2026. A compound annual growth rate of
more than 20%.1
Clearly the cell and gene therapy market indicates immense growth
potential. But, with this massive increase, comes the need for the
research, development, testing, and manufacturing services to bring
these products to patients quickly, efficiently, and with this highest
possible quality and safety.
Eurofins BioPharma Product Testing (Eurofins BPT) supports the
development of ATMPs both for traditional use as well as for use in
personalized medicine. The company provides comprehensive cGMP
APR Nov/Dec 2022

Table of Contents for the Digital Edition of APR Nov/Dec 2022
